Corvus Pharmaceuticals Inc (CRVS)
$2.21
+0.05
(+2.31%)▲
Insights on Corvus Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 103.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 252.9%
Performance
- $2.08$2.24$2.21
5.88%
Downside
Day's Volatility :7.14%
Upside
1.34%
- $1.05$4.19$2.21
52.49%
Downside
52 Weeks Volatility :74.94%
Upside
47.26%
Returns
| Period | Corvus Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 2.31% | 0.0% |
6 Months | 36.42% | 0.0% |
1 Year | -32.62% | 0.0% |
3 Years | -17.84% | -22.6% |
Highlights
Market Capitalization | 136.4M |
Book Value | $0.68 |
Earnings Per Share (EPS) | -0.51 |
PEG Ratio | 0.0 |
Wall Street Target Price | 7.83 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -29.33% |
Return On Equity TTM | -60.46% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -22.9M |
Diluted Eps TTM | -0.51 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.48 |
EPS Estimate Next Year | -0.53 |
EPS Estimate Current Quarter | -0.13 |
EPS Estimate Next Quarter | -0.13 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 254.3%
Technicals Summary
Sell
Neutral
Buy
Corvus Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Corvus Pharmaceuticals Inc | 15.71% | 36.42% | -32.62% | -17.84% | -45.57% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Corvus Pharmaceuticals Inc | NA | NA | 0.0 | -0.48 | -0.6 | -0.29 | NA | 0.68 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Corvus Pharmaceuticals Inc | Buy | $136.4M | -45.57% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
Orbimed Advisors, LLC
11.10%Adams Street Partners LLC
5.24%Samlyn Capital, LLC
3.75%Vanguard Group Inc
2.39%Renaissance Technologies Corp
0.94%BlackRock Inc
0.84%
Company Information
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Organization | Corvus Pharmaceuticals Inc |
Employees | 28 |
CEO | Dr. Richard A. Miller M.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.21
+2.31%
Keyarch Acquisition Corp
$2.21
+2.31%
Connexa Sports Technologies Inc
$2.21
+2.31%
Us Value Etf
$2.21
+2.31%
First Wave Biopharma Inc
$2.21
+2.31%
Global X Msci Next Emerging
$2.21
+2.31%
Fat Projects Acquisition Corp
$2.21
+2.31%
Goal Acquisitions Corp
$2.21
+2.31%
Capital Link Global Fintech
$2.21
+2.31%